West Pharma (WST) Misses Q1 EPS by 2c, Beats on Revenues; Offers FY18 EPS/Revenue Mid-Point Outlooks Above Consenus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. MU
8. DFTX
9. HOOD
10. RGNX

Go back to West Pharma (WST) Misses Q1 EPS by 2c, Beats on Revenues; Offers FY18 EPS/Revenue Mid-Point Outlooks Above Consenus

BofA/Merrill Lynch Downgrades West Pharmaceutical (WST) to Underperform

April 25, 2018 6:03 AM EDT

BofA/Merrill Lynch downgraded West Pharmaceutical (NYSE: WST) from Neutral to Underperform with a price target of $85.00 (from $100.00).

Analyst Derik de Bruin cites an increasing cautious outlook on teh business and believes the valuation is more than full.

For an analyst ratings... More